OCWP
ALNY icon

Owl Creek Wealth Partners’s Alnylam Pharmaceuticals ALNY Stock Holding History

Owl Creek Wealth Partners’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$45.2K Buy
150
+20
+15% +$6.03K 0.01% 391
2026
Q1 		$43K Buy
+130
New +$44.2K 0.02% 363

Other funds holding ALNY

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Owl Creek Wealth Partners's ALNY Position: Q2 2026 in Review

Owl Creek Wealth Partners increased its Alnylam Pharmaceuticals (ALNY) stake by 15% in Q2 2026, buying an estimated $6.03K and bringing the position to 150 shares worth $45.2K. The position accounts for 0.01% of the portfolio, ranked #391.

Owl Creek Wealth Partners first reported a position in ALNY in Q1 2026 and has held it in 2 quarters since. 733 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Owl Creek Wealth Partners held 150 shares of Alnylam Pharmaceuticals worth $45.2K as of Q2 2026.
  • Owl Creek Wealth Partners bought 20 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $6.03K.
  • Alnylam Pharmaceuticals made up 0.01% of Owl Creek Wealth Partners's portfolio in Q2 2026, its #391 holding.
  • Owl Creek Wealth Partners first reported a position in Alnylam Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 733 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Owl Creek Wealth Partners's 13F filing for Q2 2026, filed 20 Jul 2026.